Core Viewpoint - The investigation by the China Securities Regulatory Commission (CSRC) into Jiaying Pharmaceutical highlights severe governance issues within the company, exacerbated by a significant decline in revenue from its core products and ongoing management turmoil [2][3][15]. Governance and Management Issues - Jiaying Pharmaceutical is under investigation for information disclosure violations, which are seen as a culmination of long-standing governance deficiencies [3][15]. - The company has experienced a rapid turnover of key executives, including the resignation of the financial director and board secretary, raising concerns about internal governance stability [4][5]. - A lack of timely disclosure regarding related party transactions and internal control weaknesses has been identified as potential triggers for the investigation [3][5]. Financial Performance - Jiaying Pharmaceutical reported a revenue of 376.17 million yuan in 2024, a decrease of 29.46% year-on-year, marking two consecutive years of double-digit declines [6][7]. - The net profit attributable to shareholders fell to 20.61 million yuan, down 39.94% from the previous year, with a net profit margin dropping from 6.44% in 2023 to 5.48% in 2024 [6][7]. - The company's core products, particularly the Jieguzhili Pian/Capsule, saw a revenue decline of 41.05%, significantly impacting overall performance [9][10]. Market and Product Dynamics - The ongoing pressure from national traditional Chinese medicine procurement policies has led to a dual impact of declining prices and sales volumes for Jiaying Pharmaceutical's key products [9][10]. - The company’s revenue structure is imbalanced, with major products underperforming and insufficient growth from secondary products, leading to a "main force slowdown, new force insufficiency" scenario [9][10]. Research and Development Concerns - Jiaying Pharmaceutical's R&D expenditure decreased by 33.09% in 2024, raising concerns about its long-term competitiveness and innovation capabilities [14][15]. - The reduction in R&D personnel from 42 to 30 indicates a shrinking focus on innovation, which is critical in the increasingly competitive pharmaceutical industry [14][15]. Recent Developments - In the first quarter of 2025, Jiaying Pharmaceutical reported a revenue increase of 28.83% year-on-year, attributed to expanded sales channels, although this was not accompanied by improved cash flow [11][12]. - Despite a temporary recovery in performance, the ongoing decline in R&D investment poses risks to the company's future growth and sustainability [14][15].

关于股份回购进展情况的公告 本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 一、回购方案的主要内容 广东嘉应制药股份有限公司（以下简称"公司"）于2024年12月12日召开的第 七届董事会第四次临时会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金以集中竞价方式回购部分公司已发行的人民币普通股（A股） 股票，回购的股份将用于实施员工持股计划或股权激励，本次拟回购股份数量为 不少于700万股（含），且不超过1,350万股（含），按照回购股份数量上限1,350 万股（含）、回购股份价格上限9.80元/股（含）测算，回购股份的总金额不超过 13,230.00万元（含），具体回购股份的金额以回购实施完成时实际回购使用的金 额为准。本次回购的实施期限为自公司董事会审议通过本次回购股份方案之日起 12个月内。详见公司于2024年12月14日在《证券时报》《中国证券报》《证券日 报》及巨潮资讯网（www.cninfo.com.cn）上披露的《第七届董事会第四次临时会 议决议公告》（公告编号：2024-050）及《广东嘉应制药股份有限公司关于回购 公司股份方案的 ...

Core Viewpoint - The company, Jiaying Pharmaceutical, is facing significant governance and compliance issues, including violations of information disclosure regulations and internal control deficiencies, which have led to regulatory scrutiny and potential legal consequences [1][2][5]. Group 1: Information Disclosure Violations - Jiaying Pharmaceutical has been found to have concealed related party transactions and fund misappropriation, with transactions totaling 10.39 million yuan that were not submitted for board approval or timely disclosed [2]. - From September 2024 to January 2025, the company's subsidiary transferred 235 million yuan to related parties without board approval, violating corporate governance laws [2]. Group 2: Governance Crisis - A wave of resignations among key management personnel, including the board secretary and CFO, has raised concerns about the stability of the company's governance structure [3]. - The second largest shareholder, Yangtianhe, acquired a 7% stake in Jiaying Pharmaceutical for 355 million yuan but subsequently pledged all shares, indicating financial pressure and potential conflicts of interest [3]. Group 3: Financial Performance Concerns - In 2024, the company's revenue declined by 29.46%, with a 41.05% drop in sales of its main product, indicating weakening market competitiveness [4]. - Despite a 197.23% increase in net profit in Q1 2025, the company's operating cash flow turned negative, raising concerns about the quality of earnings and potential revenue recognition issues [4]. Group 4: Regulatory and Investor Impact - The accounting firm issued a report highlighting the company's internal control and disclosure deficiencies, which could lead to penalties, market bans, or even delisting if violations are confirmed [5]. - Legal actions for investor compensation have been initiated, with potential claims for losses incurred by investors who bought shares before May 28, 2025, and sold or held them after [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：@证券市场周刊微博 日前，嘉应制药（维权）（002198.SZ）发布公告，公司因涉嫌信息披露违法违规被中国证监会立案。 这已不是公司第一次受到监管部门处罚。此前在2021年10月、2022年6月公司曾因信息披露违规分别收到中国证监 会和广东证监局的警示函。 公告编号:2025-033 广东嘉应制药股份有限公司 关于收到中国证券监督管理委员会立案告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 颇为巧合的是，就在公司一季报发布不久的2025年5月20日，公司又发布了财务总监辞职的公告。而截至2025年5月 20日，公司有股东24009户。 此次嘉应制药被立案，如果证监会经过调查，最终对公司实施行政处罚，根据相关司法解释，在2025年5月28日收 盘之前买入公司股票，且在2025年5月28日后卖出或仍持有并曾产生一定浮亏（无论是否解套）的投资者，可通过 法律途径维护自身合法权益，最终索赔条件与获赔金额将以法院认定为准。 相关事宜可关注《证券市场周刊》微信公众号（ID：capitalweek），点击 ...

5月28日晚，广东嘉应制药（002198）股份有限公司(以下简称"嘉应制药")发布公告，公司收到中国证 券监督管理委员会的《立案告知书》，因涉嫌信息披露违法违规，中国证监会决定对公司立案。 同时，嘉应制药还存在关联方及关联交易未经审议且未披露等情况。2024年，嘉应制药及子公司与养天 和及其实际控制的公司——广东共合医药有限公司(下称"共合医药")发生关联交易金额合计1039.93万 元。但该日常关联交易未履行审议程序和披露，直到今年4月，嘉应制药才对上述关联交易予以补充披 露。 股权变更后高层动荡 嘉应制药出现的这一系列内控问题均与其第二大股东养天和存在一定关联。而养天和入股嘉应制药仅不 足一年时间。 2024年7月，嘉应制药持股5%以上股东陈少彬与养天和签署《股份转让协议》，陈少彬向养天和以每股 10元的价格转让其持有的嘉应制药7%的股份，股份转让价款合计3.55亿元。一个月后，养天和实际控 制人李能被选举为嘉应制药董事长。2024年9月，相关转让股份完成过户登记手续，养天和正式成为嘉 应制药第二大股东。 李能入主董事会后，嘉应制药不仅问题频出，高层也频繁出现变动。 前不久，嘉应制药刚被爆出内部控制存在重 ...

一周前，嘉应制药任职10个月的财务总监史俊平辞职。 嘉应制药主要从事中成药的研发、生产和销售，2007年12月登陆A股市场。上市以来，公司经营业绩整 体上不理想。2023年、2024年，公司营收净利双降，今年一季度，公司实现的归属母公司股东的净利润 （以下简称"归母净利润"）大增近2倍，但也只有1540万元。 长江商报消息 ●长江商报记者 沈右荣 老牌医药企业嘉应制药（002198.SZ）被立案调查了。 5月28日晚间，嘉应制药公告，当日，公司收到中国证监会的《立案告知书》，因公司涉嫌信息披露违 法违规，证监会决定对公司立案。对于具体所涉何事，嘉应制药在公告中没有提及。 Wind数据显示，上市18年来，嘉应制药累计盈利仅2.75亿元，累计仅进行5次现金分红，累计分红额不 到9000万元。 2024年，嘉应制药研发费用仅为675.72万元，销售费用1.37亿元。 嘉应制药靠什么突围？ 信披违规被立案调查 2020年8月，嘉应制药股东承诺12个月内增持不低于5%的股份，在延长12个月后，也仅增持0.16%的股 份，被广东证监局出具警示函，责令整改。当月，控股股东涉及表决权委托事宜，但未并告知嘉应制 药，未予以披露 ...

此外，独立董事李善伟的违规行为也令人咋舌。2024年12月，李善伟因隐瞒持股信息并在内幕信息敏感 期违规减持股票，被广东证监局采取责令购回违规减持股份的行政监管措施。其行为严重违反了信息披 露相关规定，损害了市场的公平性和投资者的利益。 嘉应制药此前还出现了多名高管职务异动，无疑给公司带来了更大的不确定性。 关联交易不规范是嘉应制药的一大问题。2024年第四季度，公司与养天和大药房股份有限公司及其关联 公司发生多笔关联交易，涉及金额高达1039.94万元，却未及时履行审议程序和披露，直至2025年4月才 补充披露。这种不规范操作严重损害了信息披露的及时性和准确性，让投资者难以及时了解公司的真实 经营状况。 资金管理漏洞同样严重。2024年9月至2025年1月期间，嘉应制药被关联方湖南药聚能医药有限公司非经 营性占用资金2.35亿元，且通过"月初转出、月末前转回"的方式粉饰痕迹，直至2025年1月23日才全部 归还。这种行为不仅违反了资金管理规定，也暴露了公司内部治理的混乱。 每经评论员 杜宇 5月28日晚间，嘉应制药（SZ002198，前收盘价：6.70元，市值：34亿元）公告因涉嫌信息披露违法违 规被证监会 ...

嘉应制药（002198）一字跌停，公司公告涉嫌信息披露违法违规，遭中国证监会立案。 暗盘资金正涌入这些股票，点击速看>>> ...

Policy Developments - The National Medical Products Administration (NMPA) held a meeting on May 28 to discuss the "Clearing Source" action in the drug distribution sector, emphasizing strict enforcement of regulations and collaboration across departments to ensure drug quality and safety [2]. Drug and Device Approvals - Novartis announced on May 28 that its anti-VEGF monoclonal antibody, Brolucizumab, has been approved by the NMPA for the treatment of diabetic macular edema (DME), allowing for injections every three months after the loading phase [4]. - On the same day, the NMPA accepted the new drug application (NDA) for Rocbrutinib, a fourth-generation BTK inhibitor developed by LuPeng Pharmaceutical, which is intended for adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitor treatment [5]. Capital Market Activities - Zhenmai Bio completed a C+ round financing of 280 million yuan on May 28, with participation from multiple investors, aiming to focus on "commercial ecosystem construction" and "global expansion" [7]. Industry Events - On May 27, Anmai Bio announced a global licensing agreement with Juri Biosciences for the development of KLK2 and CD3 T-cell engaging molecules for metastatic prostate cancer, with potential payments up to 210 million USD [9]. - Eli Lilly announced on May 27 that it will acquire SiteOne Therapeutics, a startup focused on developing sodium channel inhibitors for pain management, with a total deal value of up to 1 billion USD [10]. Regulatory and Compliance Issues - ST Longjin announced on May 28 that it received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to non-compliance with listing rules [12]. - ST Jiyuan's stock will be delisted on May 29, 2025, after failing to maintain a closing price above 1 yuan for 20 consecutive trading days [14]. - ST Suwu reported on May 28 that it is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, but its daily operations remain normal [15]. - Jiaying Pharmaceutical announced on May 28 that it is under investigation by the CSRC for suspected information disclosure violations and will cooperate with the regulatory body [16].